{"id":54,"date":"2005-12-26T09:41:53","date_gmt":"2005-12-26T01:41:53","guid":{"rendered":"http:\/\/www.chinacsr.com\/2005\/12\/26\/axm-pharma-receives-diabetes-treatment-approval-in-china\/"},"modified":"2005-12-26T09:41:53","modified_gmt":"2005-12-26T01:41:53","slug":"axm-pharma-receives-diabetes-treatment-approval-in-china","status":"publish","type":"post","link":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/","title":{"rendered":"AXM Pharma Receives Diabetes Treatment Approval In China"},"content":{"rendered":"<p><img decoding=\"async\" src=\"http:\/\/www.chinacsr.com\/images\/axmpharma_logo_120x60.gif\" width=\"120\" height=\"60\" align=\"right\">AXM Pharma's wholly-owned subsidiary in Shenyang has received approval from the Chinese Food and Drug Administration to sell Glucostrim Anti-diabetes Capsules in China, its new treatment for diabetes.<br \/>\n<!--more--><br \/>\nThe company received a New Drug Certificate, allowing it to produce and sell the product commencing in March 2006.<\/p>\n<p>Glucostrim (Qiyao) Anti-diabetes Capsules, employing traditional Chinese medicine, are designed to raise the level of the body insulin so as to reduce the glucose, and uses natural herbal medicine extracts with the company's proprietary new technology.<\/p>\n<p>The drug has proven to be effective in clinical studies with 600 cases through 18 month conducted at Affiliate Hospital of Changchun Chinese Medicine College, Affiliate Hospital of Liaoning Chinese Medicine College, Beijing Traditional Chinese Medicine Hospital and Xiyuan Hospital of China Medicine Academy. These studies also reported that the capsules are non-toxic and do not cause adverse side effects commonly associated with other treatments.<\/p>\n<p>\"We are very excited to receive marketing approval for this promising product,\" said Weishi Wang, Chairman and CEO of AXM Pharma. \"Diabetes is a growing problem in China and internationally and this product, which has proven effective in treating diabetes without the associated side effects, provides the Company with a significant revenue opportunity.\"<\/p>\n<p>According to The Asia Times, there are now 90 million people with diabetes in Asia. Asia is home to four of the world's five largest diabetic populations &#8212; India, 33 million people with diabetes; China, 23 million; Pakistan, 9 million; and Japan, 7 million. Globally, the World Health Organization estimates the global diabetes population will grow to more than 200 million in 2010 and 330 million in 2025. The burden in Asia will increase &#8212; in less than a decade 60% of all diabetes cases globally are expected to be in Asia.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AXM Pharma's wholly-owned subsidiary in Shenyang has received approval from the Chinese Food and Drug Administration to sell Glucostrim Anti-diabetes Capsules in China, its new treatment for diabetes.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-54","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AXM Pharma Receives Diabetes Treatment Approval In China - ChinaCSR.com - Corporate Social Responsibility (CSR), Business Intelligence, and Sustainability News for China<\/title>\n<meta name=\"description\" content=\"AXM Pharma&#039;s wholly-owned subsidiary in Shenyang has received approval from the Chinese Food and Drug Administration to sell Glucostrim Anti-diabetes\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AXM Pharma Receives Diabetes Treatment Approval In China - ChinaCSR.com - Corporate Social Responsibility (CSR), Business Intelligence, and Sustainability News for China\" \/>\n<meta property=\"og:description\" content=\"AXM Pharma&#039;s wholly-owned subsidiary in Shenyang has received approval from the Chinese Food and Drug Administration to sell Glucostrim Anti-diabetes\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/\" \/>\n<meta property=\"og:site_name\" content=\"ChinaCSR.com\" \/>\n<meta property=\"article:published_time\" content=\"2005-12-26T01:41:53+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.chinacsr.com\/images\/axmpharma_logo_120x60.gif\" \/>\n<meta name=\"author\" content=\"CSR and Sustainability Editor\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@China_CSR\" \/>\n<meta name=\"twitter:site\" content=\"@China_CSR\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"CSR and Sustainability Editor\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/\"},\"author\":{\"name\":\"CSR and Sustainability Editor\",\"@id\":\"https:\/\/www.chinacsr.com\/en\/#\/schema\/person\/144aee0ef9221d5da7dba67851ea5cba\"},\"headline\":\"AXM Pharma Receives Diabetes Treatment Approval In China\",\"datePublished\":\"2005-12-26T01:41:53+00:00\",\"dateModified\":\"2005-12-26T01:41:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/\"},\"wordCount\":288,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.chinacsr.com\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/www.chinacsr.com\/images\/axmpharma_logo_120x60.gif\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/\",\"url\":\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/\",\"name\":\"AXM Pharma Receives Diabetes Treatment Approval In China - ChinaCSR.com - Corporate Social Responsibility (CSR), Business Intelligence, and Sustainability News for China\",\"isPartOf\":{\"@id\":\"https:\/\/www.chinacsr.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/www.chinacsr.com\/images\/axmpharma_logo_120x60.gif\",\"datePublished\":\"2005-12-26T01:41:53+00:00\",\"dateModified\":\"2005-12-26T01:41:53+00:00\",\"description\":\"AXM Pharma's wholly-owned subsidiary in Shenyang has received approval from the Chinese Food and Drug Administration to sell Glucostrim Anti-diabetes\",\"breadcrumb\":{\"@id\":\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#primaryimage\",\"url\":\"http:\/\/www.chinacsr.com\/images\/axmpharma_logo_120x60.gif\",\"contentUrl\":\"http:\/\/www.chinacsr.com\/images\/axmpharma_logo_120x60.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.chinacsr.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AXM Pharma Receives Diabetes Treatment Approval In China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.chinacsr.com\/en\/#website\",\"url\":\"https:\/\/www.chinacsr.com\/en\/\",\"name\":\"ChinaCSR.com\",\"description\":\"Corporate Social Responsibility (CSR), Business Intelligence, and Sustainability News for China\",\"publisher\":{\"@id\":\"https:\/\/www.chinacsr.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.chinacsr.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.chinacsr.com\/en\/#organization\",\"name\":\"ChinaCSR.com\",\"url\":\"https:\/\/www.chinacsr.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.chinacsr.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.chinacsr.com\/en\/wp-content\/uploads\/chinacsr-logo-large.jpg\",\"contentUrl\":\"https:\/\/www.chinacsr.com\/en\/wp-content\/uploads\/chinacsr-logo-large.jpg\",\"width\":800,\"height\":620,\"caption\":\"ChinaCSR.com\"},\"image\":{\"@id\":\"https:\/\/www.chinacsr.com\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/China_CSR\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.chinacsr.com\/en\/#\/schema\/person\/144aee0ef9221d5da7dba67851ea5cba\",\"name\":\"CSR and Sustainability Editor\",\"sameAs\":[\"http:\/\/www.chinacsr.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AXM Pharma Receives Diabetes Treatment Approval In China - ChinaCSR.com - Corporate Social Responsibility (CSR), Business Intelligence, and Sustainability News for China","description":"AXM Pharma's wholly-owned subsidiary in Shenyang has received approval from the Chinese Food and Drug Administration to sell Glucostrim Anti-diabetes","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/","og_locale":"en_US","og_type":"article","og_title":"AXM Pharma Receives Diabetes Treatment Approval In China - ChinaCSR.com - Corporate Social Responsibility (CSR), Business Intelligence, and Sustainability News for China","og_description":"AXM Pharma's wholly-owned subsidiary in Shenyang has received approval from the Chinese Food and Drug Administration to sell Glucostrim Anti-diabetes","og_url":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/","og_site_name":"ChinaCSR.com","article_published_time":"2005-12-26T01:41:53+00:00","og_image":[{"url":"http:\/\/www.chinacsr.com\/images\/axmpharma_logo_120x60.gif","type":"","width":"","height":""}],"author":"CSR and Sustainability Editor","twitter_card":"summary_large_image","twitter_creator":"@China_CSR","twitter_site":"@China_CSR","twitter_misc":{"Written by":"CSR and Sustainability Editor","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#article","isPartOf":{"@id":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/"},"author":{"name":"CSR and Sustainability Editor","@id":"https:\/\/www.chinacsr.com\/en\/#\/schema\/person\/144aee0ef9221d5da7dba67851ea5cba"},"headline":"AXM Pharma Receives Diabetes Treatment Approval In China","datePublished":"2005-12-26T01:41:53+00:00","dateModified":"2005-12-26T01:41:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/"},"wordCount":288,"commentCount":0,"publisher":{"@id":"https:\/\/www.chinacsr.com\/en\/#organization"},"image":{"@id":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#primaryimage"},"thumbnailUrl":"http:\/\/www.chinacsr.com\/images\/axmpharma_logo_120x60.gif","articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/","url":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/","name":"AXM Pharma Receives Diabetes Treatment Approval In China - ChinaCSR.com - Corporate Social Responsibility (CSR), Business Intelligence, and Sustainability News for China","isPartOf":{"@id":"https:\/\/www.chinacsr.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#primaryimage"},"image":{"@id":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#primaryimage"},"thumbnailUrl":"http:\/\/www.chinacsr.com\/images\/axmpharma_logo_120x60.gif","datePublished":"2005-12-26T01:41:53+00:00","dateModified":"2005-12-26T01:41:53+00:00","description":"AXM Pharma's wholly-owned subsidiary in Shenyang has received approval from the Chinese Food and Drug Administration to sell Glucostrim Anti-diabetes","breadcrumb":{"@id":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#primaryimage","url":"http:\/\/www.chinacsr.com\/images\/axmpharma_logo_120x60.gif","contentUrl":"http:\/\/www.chinacsr.com\/images\/axmpharma_logo_120x60.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/www.chinacsr.com\/en\/2005\/12\/26\/54-axm-pharma-receives-diabetes-treatment-approval-in-china\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.chinacsr.com\/en\/"},{"@type":"ListItem","position":2,"name":"AXM Pharma Receives Diabetes Treatment Approval In China"}]},{"@type":"WebSite","@id":"https:\/\/www.chinacsr.com\/en\/#website","url":"https:\/\/www.chinacsr.com\/en\/","name":"ChinaCSR.com","description":"Corporate Social Responsibility (CSR), Business Intelligence, and Sustainability News for China","publisher":{"@id":"https:\/\/www.chinacsr.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.chinacsr.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.chinacsr.com\/en\/#organization","name":"ChinaCSR.com","url":"https:\/\/www.chinacsr.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.chinacsr.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.chinacsr.com\/en\/wp-content\/uploads\/chinacsr-logo-large.jpg","contentUrl":"https:\/\/www.chinacsr.com\/en\/wp-content\/uploads\/chinacsr-logo-large.jpg","width":800,"height":620,"caption":"ChinaCSR.com"},"image":{"@id":"https:\/\/www.chinacsr.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/China_CSR"]},{"@type":"Person","@id":"https:\/\/www.chinacsr.com\/en\/#\/schema\/person\/144aee0ef9221d5da7dba67851ea5cba","name":"CSR and Sustainability Editor","sameAs":["http:\/\/www.chinacsr.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.chinacsr.com\/en\/wp-json\/wp\/v2\/posts\/54","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chinacsr.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.chinacsr.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.chinacsr.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chinacsr.com\/en\/wp-json\/wp\/v2\/comments?post=54"}],"version-history":[{"count":0,"href":"https:\/\/www.chinacsr.com\/en\/wp-json\/wp\/v2\/posts\/54\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.chinacsr.com\/en\/wp-json\/wp\/v2\/media?parent=54"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.chinacsr.com\/en\/wp-json\/wp\/v2\/categories?post=54"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.chinacsr.com\/en\/wp-json\/wp\/v2\/tags?post=54"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}